Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation.
application
continuous glucose monitoring
decision-making
diabetes
digital therapeutics
effectiveness
engagement
glucose
glycemic
glycemic control
mobile application
model
monitoring
type 2 diabetes
Journal
JMIR diabetes
ISSN: 2371-4379
Titre abrégé: JMIR Diabetes
Pays: Canada
ID NLM: 101719410
Informations de publication
Date de publication:
03 May 2023
03 May 2023
Historique:
received:
07
10
2022
accepted:
07
03
2023
revised:
31
01
2023
medline:
3
5
2023
pubmed:
3
5
2023
entrez:
3
5
2023
Statut:
epublish
Résumé
Digital therapeutic platforms facilitate health care through patient-centered strategies based on multidisciplinary teams and shared decision-making. Such platforms can be used for developing a dynamic model of diabetes care delivery, which can help in improving glycemic control by promoting long-term behavior changes in people with diabetes. This study aims to evaluate the real-world effectiveness of the Fitterfly Diabetes CGM digital therapeutics program for improving glycemic control in people with type 2 diabetes mellitus (T2DM) after the completion of 90 days in the program. We analyzed deidentified data of 109 participants in the Fitterfly Diabetes CGM program. This program was delivered through the Fitterfly mobile app coupled with continuous glucose monitoring (CGM) technology. This program consists of 3 phases: the first phase is observation, wherein the patient's CGM readings are observed for 7 days (week 1); the second phase is the intervention; and the third phase aims at sustaining the lifestyle modification introduced during the second phase. The primary outcome of our study was the change in the participants' hemoglobin A At the end of the 90 days of the program, the mean HbA Our study shows that participants in the Fitterfly Diabetes CGM program showed a significant improvement in their glycemic control and reduction in weight and BMI. They also showed a high level of engagement with the program. Weight reduction was significantly associated with higher participant engagement with the program. Thus, this digital therapeutic program can be considered as an effective tool for improving glycemic control in people with T2DM.
Sections du résumé
BACKGROUND
BACKGROUND
Digital therapeutic platforms facilitate health care through patient-centered strategies based on multidisciplinary teams and shared decision-making. Such platforms can be used for developing a dynamic model of diabetes care delivery, which can help in improving glycemic control by promoting long-term behavior changes in people with diabetes.
OBJECTIVE
OBJECTIVE
This study aims to evaluate the real-world effectiveness of the Fitterfly Diabetes CGM digital therapeutics program for improving glycemic control in people with type 2 diabetes mellitus (T2DM) after the completion of 90 days in the program.
METHODS
METHODS
We analyzed deidentified data of 109 participants in the Fitterfly Diabetes CGM program. This program was delivered through the Fitterfly mobile app coupled with continuous glucose monitoring (CGM) technology. This program consists of 3 phases: the first phase is observation, wherein the patient's CGM readings are observed for 7 days (week 1); the second phase is the intervention; and the third phase aims at sustaining the lifestyle modification introduced during the second phase. The primary outcome of our study was the change in the participants' hemoglobin A
RESULTS
RESULTS
At the end of the 90 days of the program, the mean HbA
CONCLUSIONS
CONCLUSIONS
Our study shows that participants in the Fitterfly Diabetes CGM program showed a significant improvement in their glycemic control and reduction in weight and BMI. They also showed a high level of engagement with the program. Weight reduction was significantly associated with higher participant engagement with the program. Thus, this digital therapeutic program can be considered as an effective tool for improving glycemic control in people with T2DM.
Identifiants
pubmed: 37133922
pii: v8i1e43292
doi: 10.2196/43292
pmc: PMC10193208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e43292Informations de copyright
©Shilpa Joshi, Ritika Verma, Tejal Lathia, Chitra Selvan, Snehal Tanna, Amit Saraf, Mangesh Tiwaskar, Alok Modi, Sanjay Kalra, Vasudevarao K, Manoj Chitale, Forum Malde, Mohammed Abdul Khader, Arbinder Kumar Singal. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 03.05.2023.
Références
Diabetes Care. 2019 Mar;42(3):400-405
pubmed: 30352896
Circulation. 2015 Sep 8;132(10):923-31
pubmed: 26152709
J Gen Intern Med. 2019 Feb;34(2):320-324
pubmed: 30350030
Diabetes Care. 2014 Aug;37(8):2359-65
pubmed: 24812434
Diabetes Educ. 2011 May-Jun;37(3):381-91
pubmed: 21454887
Curr Diabetes Rev. 2015;11(4):222-30
pubmed: 25901504
Diabetes Res Clin Pract. 2022 Jan;183:109119
pubmed: 34879977
Diabetes Care. 2022 Feb 1;45(2):484-494
pubmed: 35050365
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Diabetol Metab Syndr. 2022 Apr 1;14(1):48
pubmed: 35365189
Indian J Endocrinol Metab. 2013 Jul;17(4):594-601
pubmed: 23961474
Diabetes Metab Res Rev. 2018 Nov;34(8):e3047
pubmed: 30028067
Int J Diabetes Dev Ctries. 2022 Jul 22;:1-8
pubmed: 35892065
Indian J Endocrinol Metab. 2014 May;18(3):370-8
pubmed: 24944934
Indian J Endocrinol Metab. 2021 Jul-Aug;25(4):342-347
pubmed: 35136743
J Med Internet Res. 2020 Aug 28;22(8):e21778
pubmed: 32856597
Front Cardiovasc Med. 2020 Sep 18;7:570553
pubmed: 33195459
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):351-354
pubmed: 32311652
Diabetes Metab Syndr Obes. 2019 Jul 19;12:1189-1199
pubmed: 31410044
BMJ. 2018 Jun 13;361:k2234
pubmed: 29898883
J Diabetes Res. 2016;2016:6989453
pubmed: 27822482
Diabetes. 2005 Jan;54(1):1-7
pubmed: 15616004
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Cardiovasc Diabetol. 2021 Jan 7;20(1):9
pubmed: 33413392
Cardiovasc Diabetol. 2020 Jul 4;19(1):102
pubmed: 32622354
J Assoc Physicians India. 2009 Feb;57:163-70
pubmed: 19582986
Clin Diabetes. 2016 Apr;34(2):70-80
pubmed: 27092016
Cell. 2015 Nov 19;163(5):1079-1094
pubmed: 26590418
Curr Med Res Opin. 2020 Sep;36(9):1441-1447
pubmed: 32643451
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
J Postgrad Med. 2014 Jul-Sep;60(3):270-5
pubmed: 25121366